Multicenter randomized phase 2 trial of CLDN18.2-specific CAR T-cell therapy versus physician’s choice for previously treated advanced gastric cancer
Prof. Lin Shen
A multicenter randomized phase 2 trial in China compared the CLDN18.2-specific CAR T-cell therapy satri-cel versus treatment of physician’s choice (TPC) in patients with CLDN18.2-positive advanced gastric or gastro-esophageal junction cancer. The median progression-free survival was 3.25 months in the satri-cel group and 1.77 months in the TPC group. Satri-cel had a manageable safety profile. This was the first randomized controlled trial of CAR T-cell therapy in solid tumors globally.
